Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition

Accumulation and deposition of amyloid-β (Aβ) in the brain represent an early and perhaps necessary step in the pathogenesis of Alzheimer's disease (AD). Aβ accumulation leads to the formation of Aβ aggregates, which may directly and indirectly lead to eventual neurodegeneration. While Aβ production is accelerated in many familial forms of early-onset AD, increasing evidence indicates that impaired clearance of Aβ is more evident in late-onset AD. To uncover the mechanisms underlying impaired Aβ clearance in AD, we examined the role of low-density lipoprotein receptor-related protein 1 (LRP1) in astrocytes. Although LRP1 has been shown to play critical roles in brain Aβ metabolism in neurons and vascular mural cells, its role in astrocytes, the most abundant cell type in the brain responsible for maintaining neuronal homeostasis, remains unclear. Here, we show that astrocytic LRP1 plays a critical role in brain Aβ clearance. LRP1 knockdown in primary astrocytes resulted in decreased cellular Aβ uptake and degradation. In addition, silencing of LRP1 in astrocytes led to downregulation of several major Aβ-degrading enzymes, including matrix metalloproteases MMP2, MMP9, and insulin-degrading enzyme. More important, conditional knock-out of the Lrp1 gene in astrocytes in the background of APP/PS1 mice impaired brain Aβ clearance, exacerbated Aβ accumulation, and accelerated amyloid plaque deposition without affecting its production. Together, our results demonstrate that astrocytic LRP1 plays an important role in Aβ metabolism and that restoring LRP1 expression and function in the brain could be an effective strategy to facilitate Aβ clearance and counter amyloid pathology in AD. SIGNIFICANCE STATEMENT Astrocytes represent a major cell type regulating brain homeostasis; however, their roles in brain clearance of amyloid-β (Aβ) and underlying mechanism are not clear. In this study, we used both cellular models and conditional knock-out mouse models to address the role of a critical Aβ receptor, the low-density lipoprotein receptor-related protein 1 (LRP1) in astrocytes. We found that LRP1 in astrocytes plays a critical role in brain Aβ clearance by modulating several Aβ-degrading enzymes and cellular degradation pathways. Our results establish a critical role of astrocytic LRP1 in brain Aβ clearance and shed light on specific Aβ clearance pathways that may help to establish new targets for AD prevention and therapy.

[1]  E. Hol,et al.  Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease , 2016, Progress in Neurobiology.

[2]  Bradley T. Hyman,et al.  Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes , 2016, Proceedings of the National Academy of Sciences.

[3]  G. Bu,et al.  Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan , 2016, Molecular Neurodegeneration.

[4]  B. Zlokovic,et al.  Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. , 2016, Biochimica et biophysica acta.

[5]  D. Holtzman,et al.  Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer’s disease , 2016, Science Translational Medicine.

[6]  T. Bayer,et al.  Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrier. , 2015, The Journal of clinical investigation.

[7]  G. Hu,et al.  Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits , 2015, Molecular Neurodegeneration.

[8]  B. Zlokovic,et al.  Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease: the role, regulation and restoration of LRP1 , 2015, Front. Aging Neurosci..

[9]  I. Lombardo,et al.  The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study , 2015, Alzheimer's & Dementia.

[10]  G. Bu,et al.  Neuronal LRP1 Regulates Glucose Metabolism and Insulin Signaling in the Brain , 2015, The Journal of Neuroscience.

[11]  Huaxi Xu,et al.  Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice , 2015, Molecular Neurodegeneration.

[12]  J. Rogers,et al.  Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimer’s Disease , 2014, Neuron.

[13]  Qingli Xiao,et al.  Enhancing Astrocytic Lysosome Biogenesis Facilitates Aβ Clearance and Attenuates Amyloid Plaque Pathogenesis , 2014, The Journal of Neuroscience.

[14]  Jianmiao Liu,et al.  Mechanisms of U87 Astrocytoma Cell Uptake and Trafficking of Monomeric versus Protofibril Alzheimer’s Disease Amyloid-β Proteins , 2014, PloS one.

[15]  G. Bu,et al.  The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer’s disease , 2014, Front. Aging Neurosci..

[16]  Pritam Das,et al.  Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. , 2014, Brain : a journal of neurology.

[17]  R. Maccioni,et al.  Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches , 2014, Front. Cell. Neurosci..

[18]  G. Bu,et al.  Retinoic Acid Isomers Facilitate Apolipoprotein E Production and Lipidation in Astrocytes through the Retinoid X Receptor/Retinoic Acid Receptor Pathway* , 2014, The Journal of Biological Chemistry.

[19]  D. Holtzman,et al.  Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1 , 2013, The Journal of Neuroscience.

[20]  H. Emonard,et al.  LRP-1: A Checkpoint for the Extracellular Matrix Proteolysis , 2013, BioMed research international.

[21]  M. Meraz-Ríos,et al.  Inflammatory process in Alzheimer's Disease , 2013, Front. Integr. Neurosci..

[22]  A. Shah,et al.  ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions , 2013, Proceedings of the National Academy of Sciences.

[23]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[24]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[25]  Andrew W. Kraft,et al.  Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  D. Holtzman,et al.  Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis , 2012, The Journal of experimental medicine.

[27]  Jie Li,et al.  LRP1 in Brain Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer's Amyloid-β , 2012, The Journal of Neuroscience.

[28]  Jie Li,et al.  Differential Regulation of Amyloid-β Endocytic Trafficking and Lysosomal Degradation by Apolipoprotein E Isoforms*♦ , 2012, The Journal of Biological Chemistry.

[29]  T. Golde,et al.  Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology , 2012, Molecular Neurodegeneration.

[30]  M. Leissring,et al.  Proteolytic degradation of amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.

[31]  D. Borchelt,et al.  Reduction of low-density lipoprotein receptor-related protein (LRP1) in hippocampal neurons does not proportionately reduce, or otherwise alter, amyloid deposition in APPswe/PS1dE9 transgenic mice , 2012, Alzheimer's Research & Therapy.

[32]  G. Hu,et al.  Aquaporin-4 mediates astrocyte response to β-amyloid , 2012, Molecular and Cellular Neuroscience.

[33]  Daniel R. Dries,et al.  Extracting β-amyloid from Alzheimer's disease , 2012, Proceedings of the National Academy of Sciences.

[34]  M. Blankenstein,et al.  The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes , 2012, Experimental Neurology.

[35]  B. Zlokovic Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[36]  J. Growdon,et al.  Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. , 2011, The American journal of pathology.

[37]  M. Mintun,et al.  Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans , 2011, Proceedings of the National Academy of Sciences.

[38]  Hui Zheng,et al.  Biology and pathophysiology of the amyloid precursor protein , 2011, Molecular Neurodegeneration.

[39]  G. Bu,et al.  Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations , 2011, Journal of Neuroscience Methods.

[40]  G. Bu,et al.  Heparan Sulphate Proteoglycan and the Low-Density Lipoprotein Receptor-Related Protein 1 Constitute Major Pathways for Neuronal Amyloid-β Uptake , 2011, The Journal of Neuroscience.

[41]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[42]  M. Sofroniew,et al.  Astrocytes: biology and pathology , 2009, Acta Neuropathologica.

[43]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[44]  D. Holtzman,et al.  Microglia Mediate the Clearance of Soluble Aβ through Fluid Phase Macropinocytosis , 2009, The Journal of Neuroscience.

[45]  Heesang Song,et al.  Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. , 2009, Cancer research.

[46]  D. Holtzman,et al.  The Low Density Lipoprotein Receptor-related Protein 1 Mediates Uptake of Amyloid β Peptides in an in Vitro Model of the Blood-Brain Barrier Cells* , 2008, Journal of Biological Chemistry.

[47]  A. Bordey,et al.  The astrocyte odyssey , 2008, Progress in Neurobiology.

[48]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[49]  L. Muglia,et al.  Amyloid Precursor Protein Regulates Brain Apolipoprotein E and Cholesterol Metabolism through Lipoprotein Receptor LRP1 , 2007, Neuron.

[50]  A. Goate,et al.  Clearance of amyloid-β by circulating lipoprotein receptors , 2007, Nature Medicine.

[51]  D. Holtzman,et al.  Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism , 2006, The Journal of Neuroscience.

[52]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[53]  M. Fornerod,et al.  Characterization of the Drosophila melanogaster genome at the nuclear lamina , 2006, Nature Genetics.

[54]  Yonghe Li,et al.  Rapid Endocytosis of the Low Density Lipoprotein Receptor-related Protein Modulates Cell Surface Distribution and Processing of the β-Amyloid Precursor Protein* , 2005, Journal of Biological Chemistry.

[55]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[56]  Bruce J Aronow,et al.  ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.

[57]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[58]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[59]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[60]  William C Hahn,et al.  Lentivirus-delivered stable gene silencing by RNAi in primary cells. , 2003, RNA.

[61]  D. Selkoe,et al.  The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics , 2002, Science.

[62]  D. Gutmann,et al.  Astrocyte-Specific Inactivation of the Neurofibromatosis 1 Gene (NF1) Is Insufficient for Astrocytoma Formation , 2002, Molecular and Cellular Biology.

[63]  D. Strickland,et al.  LRP: a multifunctional scavenger and signaling receptor. , 2001, The Journal of clinical investigation.

[64]  R. Katzman.,et al.  Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. , 2000, The Journal of clinical investigation.

[65]  B. Hyman,et al.  Modulation of β-Amyloid Precursor Protein Processing by the Low Density Lipoprotein Receptor-related Protein (LRP) , 2000, The Journal of Biological Chemistry.

[66]  R. Hammer,et al.  Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. , 1998, The Journal of clinical investigation.

[67]  Michael J. Cullen,et al.  Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40) , 1996, The Journal of Neuroscience.

[68]  H. Geuze,et al.  39 kDa receptor‐associated protein is an ER resident protein and molecular chaperone for LDL receptor‐related protein. , 1995, The EMBO journal.

[69]  T. Bayer,et al.  Endothelial LRP 1 transports amyloid-β 1 – 42 across the blood-brain barrier , 2015 .

[70]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[71]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[72]  A. Goate,et al.  Clearance of amyloid-beta by circulating lipoprotein receptors. , 2007, Nature medicine.

[73]  D. Borchelt,et al.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.

[74]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.

[75]  Opposing effects of , 2022 .